OFLO 200 MG BT 1
Product informations
They are reserved for the hospital sector and limited in adults :
To severe infections caused by [G-] bacilli and sensitive staphylococci in their manifestations:
- Septicemia.
- Respiratory.
- ENT.
- Renal and urogenital, including prostatic.
- Gynecological.
- Bone and joint.
- Skin.
- Abdominal and hepatobiliary. Streptococci and pneumococci are only moderately sensitive to ofloxacin, and the product should not be prescribed as a first-line treatment when these germs are suspected.
During the treatment of infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, the emergence of resistant mutants has been described, justifying the association with another antibiotic. Microbiological monitoring for such resistance should be considered, particularly in cases of treatment failure. The use of ofloxacin in severe infections, especially bacteremia caused by Pseudomonas aeruginosa and Acinetobacter, is not recommended. Official recommendations regarding the appropriate use of antibiotics should be taken into account.